Brief: MoonLake Immunotherapeutics Screens First Patient In Phase 2 Study Of The Nanobody® Sonelokimab In Active Psoriatic Arthritis
14/12/2022 13:20
Dec 14 (Reuters) - MoonLake Immunotherapeutics MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS SCREENS FIRST PATIENT IN PHASE
2
STUDY OF THE NANOBODY® SONELOKIMAB IN ACTIVE PSORIATIC ARTHRITIS
Source text for Eikon: ID:nGNX4ZGhs
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial